The earnings call presented a mixed view, with strong revenue growth and improved gross margins balanced by challenges in EBIT margin and segment-specific revenue declines, particularly in healthcare capital equipment and life sciences. Positive trends in free cash flow and the AST segment's growth were countered by ongoing litigation expenses and unfavorable currency impacts.

Company Guidance

During the STERIS plc Third Quarter 2025 conference call, the company provided a comprehensive overview of its financial performance and outlook. Key metrics included a 6% growth in total revenue and constant currency organic revenue, driven by volume and pricing adjustments. Gross margin improved by 90 basis points to 44.6%, while EBIT margin slightly decreased by 10 basis points to 23.3%. The adjusted effective tax rate was reported at 24.5%, and net income from continuing operations was $229 million. Adjusted earnings per diluted share increased by 11% to $2.32. The company noted capital expenditures of $299 million and free cash flow of $588 million for the first nine months, aligning with a full-year guidance of approximately $700 million. STERIS highlighted a strong backlog in healthcare with robust order growth despite some delays in capital equipment shipments. The company also adjusted its revenue growth outlook to approximately 6% due to currency impacts and maintained its free cash flow forecast, signaling confidence in its financial resilience amidst ongoing operational challenges.

Revenue Growth

Total revenue grew 6% year-over-year with constant currency organic revenue also up 6%, driven by volume and price increases.

Gross Margin Improvement

Gross margin increased by 90 basis points compared to the prior year, reaching 44.6%, driven by positive price and productivity.

Adjusted Earnings Per Share Increase

Adjusted earnings per diluted share from continuing operations increased by 11% to $2.32.

Healthcare Revenue Growth

Healthcare segment's constant currency organic revenue grew 7%, driven by strong recurring revenue streams.

AST Segment Growth

AST segment's constant currency organic revenue grew 10%, driven by a 10% increase in services.

Strong Free Cash Flow

Free cash flow for the first nine months of fiscal 2025 was $588 million, on track to meet the full-year guidance of $700 million.

---

Steris (STE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

STE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 20, 2025	2025 (Q4)	2.60 / -	2.41	―	―	―
Feb 05, 2025	2025 (Q3)	2.32 / 2.32	2.22	4.50% (+0.10)	―
Nov 06, 2024	2025 (Q2)	2.12 / 2.14	2.03	5.42% (+0.11)	―
Aug 06, 2024	2025 (Q1)	1.98 / 2.14	2	7.00% (+0.14)	―
May 08, 2024	2024 (Q4)	2.35 / 2.41	2.3	4.78% (+0.11)	―
Feb 07, 2024	2024 (Q3)	2.17 / 2.22	2.02	9.90% (+0.20)	―
Nov 07, 2023	2024 (Q2)	2.00 / 2.03	1.99	2.01% (+0.04)	―
Aug 01, 2023	2024 (Q1)	1.86 / 2.00	1.9	5.26% (+0.10)	―
May 10, 2023	2023 (Q4)	2.15 / 2.30	2.04	12.75% (+0.26)	―
Feb 08, 2023	2023 (Q3)	2.19 / 2.02	2.12	-4.72% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

STE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 05, 2025	$220.26	$224.86	+2.09%
Nov 06, 2024	$226.34	$214.38	-5.28%
Aug 06, 2024	$237.37	$231.77	-2.36%
May 08, 2024	$208.02	$223.76	+7.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---